19 completed, 7 unknown, 6 terminated, 1 active not recruiting. 24 Phase 2, 10 Phase 1, 4 Phase 3, 1 Not applicable.
Follow Hormone Refractory Prostate Cancer: new trials by email Literature Review of Hormone Refractory Prostate Cancer trials Research Report on Hormone Refractory Prostate Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors SHY-ONC6 - Advanced or Metastatic Solid Tumors, Triple Negative Breast Cancer (TNBC) | Phase 1 | Recruiting | SHY Therapeutics | 30 | 2026-06-24 | 2026-10-22 |
| The BARCODE 2 Study - The Use of Genetic Profiling to Guide Prostate Cancer Treatment Carboplatin - Hormone Refractory Prostate Cancer | Phase 2 | Active not recruiting | Institute of Cancer Research, United Kingdom | 305 | 2017-05-25 | 2026-02-04 |
| PD-1 Knockout Engineered T Cells for Castration Resistant Prostate Cancer PD-1 Knockout T Cells, Cyclophosphamide, IL-2 - Hormone Refractory Prostate Cancer | Withdrawn | Peking University | 2016-11-01 | 2019-03-06 | ||
| A Safety and Efficacy Study of SHR3680 in Metastatic Castration-Resistant Prostate Cancer Patients SHR3680 - Hormone Refractory Prostate Cancer, Metastatic Prostate Carcinoma | Phase 1 / Phase 2 | Unknown | Jiangsu HengRui Medicine Co., Ltd. | 197 | 2016-04-12 | 2020-05-13 |
| Molecular Phenotype Changes and Personalized Treatment for CRPC Docetaxel & Prednisone, DP & Targeted drugs, cisplatin & Etoposide - Hormone Refractory Prostate Cancer | Not applicable | Unknown | Tianjin Medical University Cancer Institute and Hospital | 150 | 2014-06-01 | 2014-08-05 |
| Dovitinib(TKI258) in Patients With Castration-resistant Prostate Cancer TKI258 - Hormone Refractory Prostate Cancer | Phase 2 | Completed | Korean Cancer Study Group | 44 | 2012-11-01 | 2021-02-18 |
| Study of Weekly Cabazitaxel for Advanced Prostate Cancer Cabazitaxel 10 mg/m2 - Hormone Refractory Prostate Cancer | Phase 2 | Completed | Spanish Oncology Genito-Urinary Group | 74 | 2012-05-01 | 2017-07-02 |
| Radiotherapy vs Observation for CRPC Hormone Refractory Prostate Cancer | Unknown | Zhengzhou University | 2000 | 2012-05-01 | 2012-05-04 | |
| Concurrent vs. Sequential Sipuleucel-T & Abiraterone Treatment in Men With Metastatic Castrate Resistant Prostate Cancer sipuleucel-T, abiraterone acetate - Prostate Cancer Metastatic, Hormone Refractory Prostate Cancer | Phase 2 | Completed | Dendreon | 69 | 2011-12-01 | 2019-03-19 |
| Cediranib Maleate With or Without Dasatinib in Patients With HRPC-Resistant to Treatment With Docetaxel cediranib maleate, dasatinib - Hormone Refractory Prostate Cancer, Recurrent Prostate Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 22 | 2010-10-01 | 2018-08-08 |
| Study of Bafetinib (INNO-406) as Treatment for Patients With Hormone-Refractory Prostate Cancer Bafetinib - Hormone Refractory Prostate Cancer | Phase 2 | Completed | CytRx | 23 | 2010-08-01 | 2011-12-15 |
| TroVax® In Subjects With Hormone Refractory Prostate Cancer (HRPC) Docetaxel, TroVax - Hormone Refractory Prostate Cancer | Phase 2 | Terminated | Oxford BioMedica | 25 | 2010-08-01 | 2020-10-19 |
| A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC) custirsen sodium, isotonic, 0.9% sodium chloride, docetaxel - Castrate-Resistant Prostate Cancer, Hormone Refractory Prostate Cancer | Phase 3 | Terminated | Achieve Life Sciences | 14 | 2010-03-01 | 2016-10-12 |
| Chemotherapy Response Monitoring With 18F-choline PET/CT in Hormone Refractory Prostate Cancer IV fluorine-18 labeled methylcholine before PET/CT - Hormone Refractory Prostate Cancer | Phase 1 / Phase 2 | Completed | Queen's Medical Center | 25 | 2009-06-01 | 2017-08-14 |
| RNActive®-Derived Therapeutic Vaccine CV9103 - Hormone Refractory Prostate Cancer | Phase 1 / Phase 2 | Terminated | University of Florida | 6 | 2009-05-01 | 2012-04-04 |
| Biomarker Study for Sunitinib and Docetaxel in Prostate Cancer Docetaxel * Sunitinib, Docetaxel - Hormone Refractory Prostate Cancer | Phase 2 | Unknown | Medical University of Vienna | 60 | 2008-11-01 | 2010-08-18 |
| A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases Radium-223 dichloride (Xofigo, BAY88-8223), Placebo, Best standard of care (BSoC) - Hormone Refractory Prostate Cancer, Bone Metastases | Phase 3 | Completed | Bayer | 921 | 2008-06-12 | 2026-02-23 |
| Phase II Study of Adenovirus/PSA Vaccine in Men With Hormone - Refractory Prostate Cancer ADENOVIRUS/PSA VACCINE - Hormone Refractory Prostate Cancer | Phase 2 | Completed | David M Lubaroff | 32 | 2007-12-01 | 2023-04-28 |
| A Study of Mycobacterium w Plus Docetaxel for Hormone Refractory Metastatic Prostate Cancer Mycobacterium w., Docetaxel - Hormone Refractory Prostate Cancer | Phase 2 | Terminated | Cadila Pharnmaceuticals | 134 | 2007-11-01 | 2012-03-12 |
| A Study Comparing AT-101 in Combination With Docetaxel and Prednisone Versus Docetaxel and Prednisone in Men With Chemotherapy-Naïve Metastatic Hormone Refractory Prostate Cancer (HRPC) AT-101, prednisone and docetaxel, placebo, prednisone and docetaxel - Hormone Refractory Prostate Cancer | Phase 2 | Completed | Ascenta Therapeutics | 220 | 2007-10-01 | 2010-11-09 |
Showing 20 of 35. Sign in to see all of them.
Prostatic Neoplasms (14) · Neoplasm Metastasis (2) · Neoplasms (2) · Adenocarcinoma (1) · Carcinoma (1) · Carcinoma, Non-Small-Cell Lung (1) · Colonic Neoplasms (1) · Disease (1) · Mesothelioma (1) · Prostatic Diseases (1) · Prostatic Hyperplasia (1) · Salivary Gland Adenoma, Pleomorphic (1) · Sarcoma (1) · Stomach Neoplasms (1) · Triple Negative Breast Neoplasms (1)
Neoplasms by Site (15) · Genital Diseases (14) · Genital Diseases, Male (14) · Genital Neoplasms, Male (14) · Male Urogenital Diseases (14) · Neoplasms (14) · Urogenital Diseases (14) · Urogenital Neoplasms (14) · Prostatic Diseases (13) · Neoplasms by Histologic Type (2) · Neoplasms, Glandular and Epithelial (2) · Neoplastic Processes (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Adenoma (1)
Docetaxel (8) · Prednisone (5) · Cisplatin (2) · cabazitaxel (2) · gossypol acetic acid (2) · radium Ra 223 dichloride (2) · 4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one (1) · Abiraterone Acetate (1) · Avemar (1) · Carboplatin (1) · Cyclophosphamide (1) · Dasatinib (1) · Denosumab (1) · Etoposide (1) · Everolimus (1)
Ascenta Therapeutics (2) · Bayer (2) · Achieve Life Sciences (1) · Agennix (1) · Alberta Health services (1) · Amgen (1) · British Columbia Cancer Agency (1) · Cadila Pharnmaceuticals (1) · Celgene (1) · CytRx (1) · Daniel George, MD (1) · David M Lubaroff (1) · Dendreon (1) · Immunicon (1) · Institute of Cancer Research, United Kingdom (1)
United States (20) · Canada (5) · China (4) · Spain (4) · United Kingdom (4) · France (3) · Israel (3) · Russia (3) · Belgium (2) · Germany (2) · Italy (2) · Netherlands (2) · Poland (2) · Argentina (1) · Australia (1)
Lance Leopold, MD (2) · Amil Lal Bhat, MD (1) · Anna C. Ferrari, MD (1) · Arun Chawla, MD (1) · Arup Kumar Mandal, MD (1) · Bernie Eigl, MD (1) · Christopher Parker, MD (1) · Daniel J George, MD (1) · Daniel Levitt, M.D., Ph.D. (1) · David M Lubaroff, PhD (1) · Derek Raghavan, M.D. (1) · Devakar Dalela, MD (1) · Dingwei Ye, M.D. (1) · Evan R Berger, MD (1)
PMID 11839651, PMID 20398925, PMID 21150709, PMID 21982118, PMID 22093187, PMID 22341993, PMID 23014524, PMID 23863050, PMID 23877659, PMID 23977665, PMID 24052017, PMID 24610703, PMID 24775727, PMID 24788563, PMID 24836273, PMID 24857093, PMID 25428917, PMID 25439694, PMID 25832684, PMID 25840395, PMID 25917876, PMID 26912444, PMID 27471580, PMID 27641687, PMID 27930924, PMID 34286638, PMID 35241087, PMID 37058234
2004 (1), N01CM00071 (1), R21CA139687 (1), U01CA070095 (1), U01CA132123 (1)